The discussion traces the evolution and impact of the PARITY trial, a landmark multicenter RCT in orthopedic oncology evaluating postoperative antibiotic duration after endoprosthetic reconstruction. Michelle Ghert highlights the decade-long collaborative effort across 12 countries, the trial’s finding that prolonged antibiotics did not reduce infection but did increase complications, and the subsequent suite of 13 secondary analyses soon to be published. The conversation emphasizes mentorship, methodological rigor, and the emergence of a global research network now driving new trials in sarcoma surveillance and metastatic bone disease. It closes with reflections on legacy, culture change, and preparing the next generation to lead large-scale clinical research.